Results 221 to 230 of about 39,266 (270)
Some of the next articles are maybe not open access.

Secukinumab for treating plaque psoriasis

Expert Opinion on Biological Therapy, 2015
Plaque psoriasis is a chronic inflammatory disease that can result in significant physical, psychological and quality of life impairments. Until recently, biologic treatment for psoriasis was limited to tumor necrosis factor-α inhibitors and an interleukin (IL)-12/23 p40 subunit inhibitor. Newly developed biologics targeting the pro-inflammatory IL-17A
Brooke, Rothstein, Alice, Gottlieb
openaire   +2 more sources

Plaque psoriasis

Practice Nursing, 2008
Psoriasis is a common condition of the skin that affects 1–2% of the UK population (British Association of Dermatologists (BAD), 2006). The effect on those who have psoriasis can be profound, not only in symptoms, but also in the effect on their social lives, both at home and at work.
openaire   +1 more source

Primary Annular Plaque‐Type Psoriasis

Pediatric Dermatology, 2005
Abstract:  We described two adolescent girls with untreated, consistently annular, plaque‐type psoriasis without pustules, a presentation that is to our knowledge, not previously described. No typical confluent plaque‐type lesions were present. The plaques in our patients resembled other entities such as tinea corporis and erythema annulare centrifugum,
Carrie Lynn, Guill   +2 more
openaire   +2 more sources

Bimekizumab versus Secukinumab in Plaque Psoriasis

New England Journal of Medicine, 2021
Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with secukinumab, which selectively inhibits interleukin-17A alone, in patients with moderate-to-severe plaque psoriasis have not been extensively examined.In this phase 3b trial, we randomly ...
Reich, Kristian   +12 more
openaire   +2 more sources

Chronic plaque psoriasis: an overview

Nursing Standard, 2002
Psoriasis can have a dramatic effect on patients' lives. Karina Jackson describes the symptoms, possible causes and treatment options and outlines the role of the nurse in assessment and ongoing management.
openaire   +2 more sources

Drugs for Plaque Psoriasis

The Medical Letter on Drugs and Therapeutics
Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with topical therapy, phototherapy, and systemic drugs have recently been published.
openaire   +2 more sources

Psoriasis (chronic plaque).

BMJ clinical evidence, 2016
Psoriasis affects 1-3% of the population, in some people causing changes to the nails and joints in addition to skin lesions.We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of systemic drug treatments, topical drug treatments, and non-drug treatments (other than ultraviolet light) for chronic ...
Luigi, Naldi, Berthold, Rzany
openaire   +1 more source

Imiquimod‐induced extensive plaque psoriasis

International Journal of Dermatology, 2023
Erica P. Abreu   +3 more
openaire   +2 more sources

Skin Plaques Mimicking Psoriasis

The Journal of Pediatrics, 2015
Jennifer, Lehmberg   +4 more
openaire   +2 more sources

Treatment of Plaque Psoriasis

New England Journal of Medicine, 2001
T P, Millard, K E, Birch, E R, Young
openaire   +2 more sources

Home - About - Disclaimer - Privacy